Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21326076 | 0.98 | CD44 (0.54) | CD44HTR2CHTR2BPNMTMAOB | |
| Hydrochloric Acid SCHEMBL29588004 | 0.98 | CD44 (0.54) | CD44HTR2CHTR2BPNMTMAOB | |
| SCHEMBL7905006 | 0.83 | HTR2C (0.44) | CD44HTR2CHTR2BPNMTHTR1A | |
| SCHEMBL27840577 | 0.81 | CD44 (0.44) | CD44HTR2CHTR2BPNMTMAOB | |
| SCHEMBL22978632 | 0.77 | RBP4 (0.42) | CD44HTR2CHTR2BHTR6HTR2A | |
| SCHEMBL24120085 | 0.76 | HTR2C (0.51) | HTR2CHTR1AHTR7HTR6 | |
| SCHEMBL23980883 | 0.75 | DDB1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL23780213 | 0.75 | HTR2C (0.53) | HTR2CHTR1AHTR7HTR6 | |
| SCHEMBL18828495 | 0.73 | HTR1A (0.50) | HTR2CHTR2BHTR1AHTR7 | |
| SCHEMBL21743786 | 0.72 | CD44 (0.45) | CD44HTR2CHTR2BPNMTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HOFFMANN-LA ROCHE, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3535256-B1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| US-20190276433-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HCCS, HAVCR2, ZC3HAV1 | CD44 4518/4885HTR2C 1328/4885HTR2B 1336/4885 |
| US-20190276433-A1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, RECQL | CD44 4354/4885HTR2C 1102/4885HTR2B 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.